

Anti-CHRD1-1 Reference Antibody (Amgen patent anti-CHRD1-1)

Catalog # APR11426

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9BU40
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-N297G-EM
Calculated MW	52026

Additional Information


Target/Specificity	CHRD1-1
Expression system	CHO

Protein Information


Name	CHRD1
Synonyms	NRLN1
Function	Antagonizes the function of BMP4 by binding to it and preventing its interaction with receptors. Alters the fate commitment of neural stem cells from gliogenesis to neurogenesis. Contributes to neuronal differentiation of neural stem cells in the brain by preventing the adoption of a glial fate. May play a crucial role in dorsoventral axis formation. May play a role in embryonic bone formation (By similarity). May also play an important role in regulating retinal angiogenesis through modulation of BMP4 actions in endothelial cells. Plays a role during anterior segment eye development.
Cellular Location	Secreted.
Tissue Location	Expressed in the developing cornea and in the eye anterior segment in addition to the retina. Differentially expressed in the fetal brain. There is high expression in cerebellum and neocortex Expressed in retinal pericytes.

Images


Anti-CHRD1-1 Reference Antibody (Amgen patent anti-CHRD1-1) on SDS-PAGE under reducing (R) condition.



The purity of the protein is greater than 95%.



The purity of Anti-CHRD-1 Reference Antibody (Amgen patent anti-CHRD-1) is 99.57%, determined by SEC-HPLC.



Immobilized hu-CHRD-1-his at 2 µg/mL can bind Amgen patent anti-CHRD-1, EC₅₀= 0.09865 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.